Cargando…

European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift

The latest Association Française pour l’Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommenda...

Descripción completa

Detalles Bibliográficos
Autores principales: Loustaud-Ratti, Véronique, Debette-Gratien, Marilyne, Carrier, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206148/
https://www.ncbi.nlm.nih.gov/pubmed/30386457
http://dx.doi.org/10.4254/wjh.v10.i10.639
_version_ 1783366312161968128
author Loustaud-Ratti, Véronique
Debette-Gratien, Marilyne
Carrier, Paul
author_facet Loustaud-Ratti, Véronique
Debette-Gratien, Marilyne
Carrier, Paul
author_sort Loustaud-Ratti, Véronique
collection PubMed
description The latest Association Française pour l’Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients’ management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the “reservoir” population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations.
format Online
Article
Text
id pubmed-6206148
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-62061482018-10-31 European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift Loustaud-Ratti, Véronique Debette-Gratien, Marilyne Carrier, Paul World J Hepatol Editorial The latest Association Française pour l’Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients’ management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the “reservoir” population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations. Baishideng Publishing Group Inc 2018-10-27 2018-10-27 /pmc/articles/PMC6206148/ /pubmed/30386457 http://dx.doi.org/10.4254/wjh.v10.i10.639 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Editorial
Loustaud-Ratti, Véronique
Debette-Gratien, Marilyne
Carrier, Paul
European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
title European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
title_full European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
title_fullStr European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
title_full_unstemmed European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
title_short European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift
title_sort european association for the study of the liver and french hepatitis c recent guidelines: the paradigm shift
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206148/
https://www.ncbi.nlm.nih.gov/pubmed/30386457
http://dx.doi.org/10.4254/wjh.v10.i10.639
work_keys_str_mv AT loustaudrattiveronique europeanassociationforthestudyoftheliverandfrenchhepatitiscrecentguidelinestheparadigmshift
AT debettegratienmarilyne europeanassociationforthestudyoftheliverandfrenchhepatitiscrecentguidelinestheparadigmshift
AT carrierpaul europeanassociationforthestudyoftheliverandfrenchhepatitiscrecentguidelinestheparadigmshift